Journal Article Summary
The article investigates the effectiveness of oral semaglutide, a medication typically used for type 2 diabetes, in treating obesity in adults without diabetes. Obesity is a significant health issue that can lead to various complications, and traditional methods like diet and exercise often fall short in achieving long-term weight loss. As the demand for effective pharmacotherapy increases, understanding the role of oral semaglutide in obesity management is crucial, especially given the challenges associated with injectable medications and drug shortages.
In this retrospective study, researchers analyzed data from 93 adults (average age 52, 57% women) who were prescribed 14 mg of oral semaglutide for obesity over one year. The results showed that participants who completed the treatment experienced an average weight loss of 5.7% and a decrease in body mass index (BMI) by 2 kg/m². Additionally, waist circumference and obesity staging scores improved, with 46% of participants achieving clinically significant weight loss. However, the study also noted that side effects were mostly mild, with nausea being the most common.
Despite these findings, the study has limitations, including its retrospective design and the potential for selection bias, as participants were self-funded and motivated to seek treatment. The results may not be generalizable to a broader population, as the study focused on Caucasian adults. Patients considering oral semaglutide should discuss their options with a healthcare professional, especially regarding the potential for side effects and the need for a comprehensive weight management plan that includes lifestyle modifications.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Krajnc Mitja, Kuhar Neža, Koceva Andrijana. Oral semaglutide for the treatment of obesity: a retrospective real-world study. Frontiers in Endocrinology 2025. DOI: 10.3389/fendo.2025.1593334. PMID: 40510489. PMCID: PMC12158668.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
